Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

AZ has already thrown down a marker for its tougher stance on Europe, with an earlier decision to abandon a $560 million ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Soriot discussed the impact of potential tariffs during a call on AstraZeneca's earnings. For the three months ended March 31, during which period the firm netted $13.59 billion in total revenue, an ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. $350M ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S.